Search

Your search keyword '"Deryck, Olivier"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Deryck, Olivier" Remove constraint Author: "Deryck, Olivier"
48 results on '"Deryck, Olivier"'

Search Results

1. Brain age as a biomarker for pathological versus healthy ageing – a REMEMBER study

3. Clinical variability and onset age modifiers in an extended Belgian GRN founder family

4. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis

5. Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum

6. Microtubule associated protein tau p.R406W patient carriers present with a nonconforming clinical phenotype

7. Alzheimer’s disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association

8. Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum

10. Frequent MAPT p.R406W Carriers with a Nonconforming FTD Phenotype in the Belgian Population (S20.006)

12. Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort

13. NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients

14. TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis

15. Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients

16. Diagnostic performance of automated MRI volumetry by icobrain DM for Alzheimer's disease in a clinical setting: A REMEMBER study

17. Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer’s Disease in a Clinical Setting: A REMEMBER Study

18. Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study.

20. Distinct Clinical Characteristics of C9orf72 Expansion Carriers Compared With GRN, MAPT, and Nonmutation Carriers in a Flanders-Belgian FTLD Cohort

21. Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability

22. Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council.

23. Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council

24. A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER).

25. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

26. A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER).

27. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis

28. No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients

29. Clinical variability and onset age modifiers in an extended Belgian GRN founder family

30. A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer’s Disease (REMEMBER)

31. Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort

32. NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients

33. TBK1Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis

34. Clinical Evidence of Disease Anticipation in Families Segregating aC9orf72Repeat Expansion

35. Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients

37. Clinical evidence for genetic anticipation in C9orf72 pedigrees

38. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter

39. Botulinum toxin infiltrations for chronic migraine are efficacious and safe: the Bruges experience

40. Clinical Evidence for Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion (S21.006)

41. Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey.

42. Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer’s disease: a BeDeCo survey

43. No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients

44. Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion.

46. Clinical Evidence for Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion

47. Ofatumumab versus Teriflunomide in Multiple Sclerosis

48. Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum.

Catalog

Books, media, physical & digital resources